Pharmacokinetics of recombinant human thrombopoietin (rhTPO) after intravenous administration in cancer patients.

被引：0
|
作者：
Bloedow, D
VadhanRaj, S
Paton, V
Johnston, T
Yang, T
Senn, T
Ashby, M
Sims, P
机构：
[1] GENENTECH INC,S SAN FRANCISCO,CA 94080
[2] MD ANDERSON CANC CTR,HOUSTON,TX 77030
来源：
BLOOD | 1996年 / 88卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1392 / 1392
页数：1
相关论文
共 50 条
  • [1] PHARMACOKINETICS OF TECELEUKIN (RECOMBINANT HUMAN INTERLEUKIN-2) AFTER INTRAVENOUS OR SUBCUTANEOUS ADMINISTRATION TO PATIENTS WITH CANCER
    GUSTAVSON, LE
    NADEAU, RW
    OLDFIELD, NF
    JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, 1989, 8 (04): : 440 - 449
  • [2] The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin
    Xenocostas, A
    Cheung, W
    Zakszewski, C
    Kelly, M
    Lutynski, A
    Crump, M
    Lipton, J
    Kiss, T
    Messner, H
    EXPERIMENTAL HEMATOLOGY, 2002, 30 (06) : 42 - 42
  • [3] The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin
    Xenocostas, A
    Cheung, WK
    Farrell, F
    Zakszewski, C
    Kelley, M
    Lutynski, A
    Crump, M
    Lipton, JH
    Kiss, TL
    Lau, CY
    Messner, HA
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (03) : 189 - 195
  • [4] The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin
    Anargyros Xenocostas
    Wing K. Cheung
    Francis Farrell
    Cindy Zakszewski
    Marian Kelley
    Andrzej Lutynski
    Michael Crump
    Jeffrey H. Lipton
    Thomas L. Kiss
    Catherine Y. Lau
    Hans A. Messner
    European Journal of Clinical Pharmacology, 2005, 61 : 189 - 195
  • [5] Recombinant human thrombopoietin (rhTPO) for treatment of prolonged thrombocytopenia after allogeneic stem cell transplantation
    Sun, Y.
    Kong, Y.
    Ji, Y.
    Zhang, S.
    Yan, C-H
    Wang, Y.
    Song, Y.
    Shi, M-M
    Huang, X-J
    BONE MARROW TRANSPLANTATION, 2017, 52 : S308 - S308
  • [6] Safety and activity of recombinant human thrombopoietin (rhTPO) in patients (pts) with delayed platelet recovery (DPR).
    Nash, R
    Kurzrock, R
    DiPersio, J
    Nimer, S
    Vose, J
    Maharaj, D
    Linker, C
    Nademanee, A
    Negrin, R
    Ashby, M
    Tremblay, T
    Jones, D
    Appelbaum, F
    Champlin, R
    BLOOD, 1997, 90 (10) : 1151 - 1151
  • [7] THE APPLICATION OF RECOMBINANT HUMAN THROMBOPOIETIN (RHTPO) IN SECONDARY PREVENTION OF CHEMOTHERAPY INDUCED THROMBOCYTOPENIA PATIENTS IN CHINA
    Yang, F.
    Li, L.
    Xuan, J.
    VALUE IN HEALTH, 2017, 20 (05) : A315 - A315
  • [8] Improvement of thrombocytopenia after bone marrow-transplantion by recombinant human thrombopoietin (rhTPO) in mice.
    Kabaya, K
    Akahori, H
    Shibuya, K
    Nitta, Y
    Kusaka, M
    Kato, T
    Miyazaki, H
    BLOOD, 1995, 86 (10) : 443 - 443
  • [9] THE PHARMACOKINETICS OF RECOMBINANT HUMAN RELAXIN IN NONPREGNANT WOMEN AFTER INTRAVENOUS, INTRAVAGINAL, AND INTRACERVICAL ADMINISTRATION
    CHEN, SA
    PERLMAN, AJ
    SPANSKI, N
    PETERSON, CM
    SANDERS, SW
    JAFFE, R
    MARTIN, M
    YALCINKAYA, T
    CEFALO, RC
    CHESCHEIR, NC
    MENARD, MK
    MORDENTI, J
    PHARMACEUTICAL RESEARCH, 1993, 10 (06) : 834 - 838
  • [10] Effects of recombinant human thrombopoietin (rhTPO) on bone marrow megakaryocytes in humans.
    Reddy, SP
    BuesoRamos, C
    Boiko, I
    Hittelman, WN
    VadhanRaj, S
    BLOOD, 1996, 88 (10) : 233 - 233
12345